INTRODUCTION: The microenvironment of low oxygen that is present in human pancreatic cancer in vivo may actively influence tumor growth as well as neovascularization. AIMS: To determine whether hypoxia-inducible factor 1 (HIF-1) is specifically activated by hypoxia in vitro in pancreatic cancer cells and correlated these findings with tumor specimens. METHODOLOGY: Hypoxic regulation of vascular endothelial growth factor (VEGF) was studied by northern blot analysis and enzyme-linked immunosorbent assay. Electrophoretic mobility shift assays and western blot analysis were used to demonstrate hypoxic activation of HIF-1. The relationship between HIF-1 and VEGF in human pancreatic cancer specimens was studied by immunohistochemical analysis, northern blot analysis, and in situ hybridization. RESULTS: Studies in vivo of human pancreatic cancer tissue showed co-localization of VEGF mRNA, which is produced in ductal cancer cells, and HIF-1alpha protein, which was detectable in cell nuclei of the same cells. HIF-1alpha mRNA expression was dramatically upregulated (approximately 13-fold) in these specimens as well. In vitro, all pancreatic cancer cell lines increased VEGF production when exposed to low oxygen levels, by highly specific activation of HIF-1 DNA binding activity to the VEGF promoter. Cancer cell lines with high constitutive levels of HIF-1alpha protein were found to produce higher basal levels of VEGF. CONCLUSION: We conclude that HIF-1 is the regulatory link between tumor hypoxia and VEGF production in pancreatic cancer, thus establishing a biochemical pathway between tumor hypoxia and neoangiogenesis in this highly aggressive neoplasm.
INTRODUCTION: The microenvironment of low oxygen that is present in humanpancreatic cancer in vivo may actively influence tumor growth as well as neovascularization. AIMS: To determine whether hypoxia-inducible factor 1 (HIF-1) is specifically activated by hypoxia in vitro in pancreatic cancer cells and correlated these findings with tumor specimens. METHODOLOGY: Hypoxic regulation of vascular endothelial growth factor (VEGF) was studied by northern blot analysis and enzyme-linked immunosorbent assay. Electrophoretic mobility shift assays and western blot analysis were used to demonstrate hypoxic activation of HIF-1. The relationship between HIF-1 and VEGF in humanpancreatic cancer specimens was studied by immunohistochemical analysis, northern blot analysis, and in situ hybridization. RESULTS: Studies in vivo of humanpancreatic cancer tissue showed co-localization of VEGF mRNA, which is produced in ductal cancer cells, and HIF-1alpha protein, which was detectable in cell nuclei of the same cells. HIF-1alpha mRNA expression was dramatically upregulated (approximately 13-fold) in these specimens as well. In vitro, all pancreatic cancer cell lines increased VEGF production when exposed to low oxygen levels, by highly specific activation of HIF-1 DNA binding activity to the VEGF promoter. Cancer cell lines with high constitutive levels of HIF-1alpha protein were found to produce higher basal levels of VEGF. CONCLUSION: We conclude that HIF-1 is the regulatory link between tumor hypoxia and VEGF production in pancreatic cancer, thus establishing a biochemical pathway between tumor hypoxia and neoangiogenesis in this highly aggressive neoplasm.
Authors: Yun Su; Peter Büchler; Amiq Gazdhar; Nathalia Giese; Howard A Reber; Oscar J Hines; Thomas Giese; Markus W Büchler; Helmut Friess Journal: J Gastrointest Surg Date: 2006-11 Impact factor: 3.452
Authors: Peter Büchler; Howard A Reber; Mendel M Roth; Mark Shiroishi; Helmut Friess; Oscar J Hines Journal: Neoplasia Date: 2007-02 Impact factor: 5.715
Authors: Peter Büchler; Amiq Gazdhar; Mario Schubert; Nathalia Giese; Howard A Reber; Oscar J Hines; Thomas Giese; Güralp O Ceyhan; Michael Müller; Markus W Büchler; Helmut Friess Journal: Ann Surg Date: 2005-12 Impact factor: 12.969
Authors: Kim Cheng; Kenneth Ho; Rebecca Stokes; Christopher Scott; Sue Mei Lau; Wayne J Hawthorne; Philip J O'Connell; Thomas Loudovaris; Thomas W Kay; Rohit N Kulkarni; Terumasa Okada; Xiaohui L Wang; Sun Hee Yim; Yatrik Shah; Shane T Grey; Andrew V Biankin; James G Kench; D Ross Laybutt; Frank J Gonzalez; C Ronald Kahn; Jenny E Gunton Journal: J Clin Invest Date: 2010-05-03 Impact factor: 14.808
Authors: Peter Büchler; Howard A Reber; James S Tomlinson; Oliver Hankinson; Georgis Kallifatidis; Helmut Friess; Ingrid Herr; Oscar J Hines Journal: Neoplasia Date: 2009-02 Impact factor: 5.715
Authors: Justin G Wilkes; Brianne R O'Leary; Juan Du; Adrienne R Klinger; Zita A Sibenaller; Claire M Doskey; Katherine N Gibson-Corley; Matthew S Alexander; Susan Tsai; Garry R Buettner; Joseph J Cullen Journal: Clin Exp Metastasis Date: 2018-02-02 Impact factor: 5.150
Authors: O Thews; T Wolloscheck; W Dillenburg; S Kraus; D K Kelleher; M A Konerding; P Vaupel Journal: Br J Cancer Date: 2004-09-13 Impact factor: 7.640